

SECURITIES AND EXCHANGE COMMISSION

FORM 8-K

Current report filing

Filing Date: **2013-01-09** | Period of Report: **2013-01-09**  
SEC Accession No. [0000897101-13-000049](#)

([HTML Version](#) on [secdatabase.com](#))

FILER

**ST JUDE MEDICAL INC**

CIK:[203077](#) | IRS No.: [411276891](#) | State of Incorp.:**MN** | Fiscal Year End: **1231**  
Type: **8-K** | Act: **34** | File No.: [001-12441](#) | Film No.: **13521008**  
SIC: **3845** Electromedical & electrotherapeutic apparatus

Mailing Address

*ONE ST JUDE MEDICAL  
DRIVE  
ST PAUL MN 55117*

Business Address

*ONE ST JUDE MEDICAL  
DRIVE  
ST PAUL MN 55117  
6517562000*

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington D.C. 20549

---

**FORM 8-K**

---

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **January 9, 2013**

---

**ST. JUDE MEDICAL, INC.**

(Exact name of registrant as specified in its charter)

**Minnesota**  
(State or other jurisdiction  
of incorporation)

**1-12441**  
(Commission  
File Number)

**41-1276891**  
(IRS Employer  
Identification No.)

**One St. Jude Medical Drive, St. Paul, MN**  
(Address of principal executive offices)

**55117**  
(Zip Code)

Registrant's telephone number, including area code: **(651) 756-2000**

**Not applicable**

(Former name or former address, if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 2.02      Results of Operations and Financial Condition.**

On January 9, 2013, St. Jude Medical, Inc. issued a press release concerning its preliminary financial results for the fourth quarter 2012. A copy of the press release is furnished as Exhibit 99.1 to this report.

**Item 9.01      Financial Statements and Exhibits.**

(d) Exhibits:

99.1      Press release issued by St. Jude Medical, Inc. on January 9, 2013.

## SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ST. JUDE MEDICAL, INC.

Date: January 9, 2013

By: /s/ Jason Zellers  
Jason Zellers  
Vice President, General  
Counsel  
and Corporate Secretary

---

## EXHIBIT INDEX

**Exhibit No.**

**Description of Exhibit**

99.1

Press release issued by St. Jude Medical, Inc. on January 9, 2013.

---



St. Jude Medical, Inc.  
Global Headquarters  
One St. Jude Medical Drive  
St. Paul, MN 55117-9913 USA  
Tel 651 756 2000  
sjm.com

# News Release

## CONTACTS:

J.C. Weigelt  
Investor Relations  
Tel 651 756 4347  
jweigelt@sjm.com

Amy Jo Meyer  
Media Relations  
Tel 651 756 3029  
ameyer@sjm.com

## St. Jude Medical Announces Preliminary Fourth Quarter Financial Results

ST. PAUL, Minn. – Jan. 9, 2013 – St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced preliminary revenue results for the fourth quarter ended Dec. 29, 2012. These results will be referenced today in a presentation by the Chairman, President and Chief Executive Officer of St. Jude Medical, Daniel J. Starks, at the 31<sup>st</sup> Annual J.P. Morgan Healthcare Conference in San Francisco. A webcast of the presentation can be accessed live on the Investor Relations section of [www.sjm.com](http://www.sjm.com), beginning at 3:30 p.m. PST.

The Company expects to report net sales of approximately \$1.372 billion for the fourth quarter of 2012, down approximately 1 percent from last year's fourth quarter after adjusting for the negative impact of foreign currency.

Commenting on preliminary fourth quarter 2012 results, Mr. Starks said, "St. Jude Medical's fourth quarter revenue fell within or exceeded all of our previously announced guidance ranges. These preliminary sales results, combined with our implementation of significant cost savings initiatives in 2012 make us comfortable that we will exceed our previously announced adjusted earnings per share guidance range by \$0.02 to \$ 0.04 for the fourth quarter."

### Cardiac Rhythm Management (CRM)

Fourth quarter CRM sales were approximately \$682 million, a 6 percent decrease compared with the fourth quarter of 2011. Total CRM sales for the fourth quarter decreased 5 percent after adjusting for the impact of foreign currency. Fourth quarter sales of implantable cardiac defibrillators were approximately \$422 million, a 3 percent decrease from the comparable quarter in 2011. Pacemaker sales during the quarter were approximately \$260 million, an 11 percent decrease compared with the fourth quarter of 2011.

### Atrial Fibrillation (AF)

Atrial Fibrillation product sales for the fourth quarter were approximately \$239 million, an increase of 10 percent over the fourth quarter of 2011. On a constant currency basis, total AF sales for the fourth quarter increased 11 percent.

### Cardiovascular

Total cardiovascular sales, which primarily include vascular and structural heart products, were \$338 million for the fourth quarter of 2012, a 1 percent decrease from the fourth quarter of 2011. Sales of vascular products in the fourth quarter of 2012 were \$186 million, a 2 percent decrease from the comparable quarter in 2011. Structural heart product sales for the

fourth quarter of 2012 were \$152 million, a 1 percent increase over the fourth quarter of 2011. Total cardiovascular sales for the fourth quarter increased 1 percent after adjusting for the impact of foreign currency.

---



St. Jude Medical, Inc.  
Global Headquarters  
One St. Jude Medical Drive  
St. Paul, MN 55117-9913 USA  
Tel 651 756 2000  
sjm.com

## **Neuromodulation**

Fourth quarter sales of neuromodulation products were approximately \$113 million, a 7 percent decrease compared to the fourth quarter of 2011. Revenue for the fourth quarter decreased 6 percent after adjusting for the impact of foreign currency.

## **Fourth Quarter Earnings Results**

St. Jude Medical now projects that its fourth quarter adjusted earnings per share will be in the range of \$0.90 to \$0.92, exceeding the top end of the Company's previously issued guidance by \$0.02 to \$0.04. Adjusted earnings per share for the fourth quarter excludes net charges totaling approximately \$0.50 to \$0.60 per share, primarily related to ongoing restructuring actions and certain other corporate charges. The Company attributes this over-performance to its sales results along with the implementation of cost savings initiatives during the quarter.

The Company will release its fourth quarter and full-year results and provide its first quarter and full-year 2013 guidance on Jan. 23 at 6:30 a.m. CST. The press release will be followed by a conference call beginning at 7:00 a.m. CST. The conference call will be broadcast live on the Investor Relations section of [sjm.com](http://sjm.com).

## **About St. Jude Medical**

St. Jude Medical develops medical technology and services that focus on putting more control into the hands of those who treat cardiac, neurological and chronic pain patients worldwide. The company is dedicated to advancing the practice of medicine by reducing risk wherever possible and contributing to successful outcomes for every patient. St. Jude Medical is headquartered in St. Paul, Minn. and has four major focus areas that include: cardiac rhythm management, atrial fibrillation, cardiovascular and neuromodulation. For more information, please visit [sjm.com](http://sjm.com).

## **Forward-Looking Statements**

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the Company, including potential clinical successes, anticipated regulatory approvals and future product launches, and projected revenues, margins, earnings and market shares. The statements made by the Company are based upon management's current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include market conditions and other factors beyond the Company's control and the risk factors and other cautionary statements described in the Company's filings with the SEC, including those described in the Risk Factors and Cautionary Statements sections of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2011 and Quarterly Report on Form 10-Q for the fiscal quarter ended September 29, 2012. The Company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.